WO2011145085A3 - Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer - Google Patents

Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer Download PDF

Info

Publication number
WO2011145085A3
WO2011145085A3 PCT/IB2011/052228 IB2011052228W WO2011145085A3 WO 2011145085 A3 WO2011145085 A3 WO 2011145085A3 IB 2011052228 W IB2011052228 W IB 2011052228W WO 2011145085 A3 WO2011145085 A3 WO 2011145085A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
diagnosis
treatment
methods
nsclc
Prior art date
Application number
PCT/IB2011/052228
Other languages
English (en)
Other versions
WO2011145085A2 (fr
Inventor
Itai Benhar
Yeshayahu Yakir
Original Assignee
Procognia (Israel) Ltd
Ramot At Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procognia (Israel) Ltd, Ramot At Tel Aviv University Ltd filed Critical Procognia (Israel) Ltd
Publication of WO2011145085A2 publication Critical patent/WO2011145085A2/fr
Publication of WO2011145085A3 publication Critical patent/WO2011145085A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux, des fragments, des fragments ou parties de liaison à l'antigène de ceux-ci, pour la liaison spécifique à des antigènes glucidiques associés aux tumeurs humaines et/ou murines exprimés sur les cellules cancéreuses, par exemple, l'adénocarcinome colorectal humain, le carcinome du poumon non à petites cellules (NSCLC). Ces anticorps peuvent être utilisés pour induire l'apoptose sélective dans les cellules cancéreuses et pour le traitement du cancer, par exemple, du NSCLC et/ou dans le diagnostic de cancers exprimant des antigènes glucidiques associés aux tumeurs in vitro et in vivo.
PCT/IB2011/052228 2010-05-21 2011-05-22 Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer WO2011145085A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34704110P 2010-05-21 2010-05-21
US61/347,041 2010-05-21

Publications (2)

Publication Number Publication Date
WO2011145085A2 WO2011145085A2 (fr) 2011-11-24
WO2011145085A3 true WO2011145085A3 (fr) 2012-03-01

Family

ID=44532963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/052228 WO2011145085A2 (fr) 2010-05-21 2011-05-22 Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer

Country Status (1)

Country Link
WO (1) WO2011145085A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7340221B2 (ja) * 2015-05-01 2023-09-07 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア グリカン依存性免疫療法分子
CN107308515A (zh) * 2016-09-29 2017-11-03 中国人民解放军总医院 一种血液中循环肿瘤细胞的灭活系统及应用
JP7010520B2 (ja) * 2017-05-12 2022-02-10 オンコターク ダイアグノスティクス カンパニー リミテッド 胆道細胞でメチオニル－ｔＲＮＡ合成酵素を利用した胆道癌の診断方法
CN113087801B (zh) * 2021-04-07 2022-07-05 深圳市核子基因科技有限公司 一种用核酸和抗体联合检测肺癌的试剂盒
WO2023244510A2 (fr) * 2022-06-13 2023-12-21 The Regents Of The University Of California Protéines bi-spécifiques immunothérapeutiques dépendantes du glycane améliorées ayant une demi-vie plus longue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153237A1 (fr) * 2007-06-13 2008-12-18 Korea Research Institute Of Bioscience And Biotechnology Anticorps monoclonal humain neutralisant le récepteur du facteur de croissance de l'endothélium vasculaire et utilisation
WO2009028580A1 (fr) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 et cdkn3 pour des gènes cibles de thérapie et de diagnostic de cancer de poumon
WO2010050528A1 (fr) * 2008-10-28 2010-05-06 塩野義製薬株式会社 Anticorps anti-muc1

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (fr) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Anticorps chimeriques specifiques au recepteur il-2
WO1989009825A1 (fr) 1988-04-16 1989-10-19 Celltech Limited Procede de production de proteines d'adn recombinant
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2166955C2 (ru) 1991-01-18 2001-05-20 Эмген Инк. Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
US6696686B1 (en) 1999-06-06 2004-02-24 Elgems Ltd. SPECT for breast cancer detection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153237A1 (fr) * 2007-06-13 2008-12-18 Korea Research Institute Of Bioscience And Biotechnology Anticorps monoclonal humain neutralisant le récepteur du facteur de croissance de l'endothélium vasculaire et utilisation
WO2009028580A1 (fr) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 et cdkn3 pour des gènes cibles de thérapie et de diagnostic de cancer de poumon
WO2010050528A1 (fr) * 2008-10-28 2010-05-06 塩野義製薬株式会社 Anticorps anti-muc1
EP2351777A1 (fr) * 2008-10-28 2011-08-03 Shionogi & Co., Ltd. Anticorps anti-muc1

Also Published As

Publication number Publication date
WO2011145085A2 (fr) 2011-11-24

Similar Documents

Publication Publication Date Title
CA3011087A1 (fr) Procedes de production d'agents therapeutiques anticancereux specifiques aux patients et procedes de traitement associes
WO2012097313A3 (fr) Anticorps thérapeutiques contre la protéine ror-1 et leurs méthodes d'utilisation
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
WO2011163401A3 (fr) Antigènes et anticorps spécifiques des cancers du côlon et du pancréas
PH12017500268A1 (en) Antibodies and chimeric antigen receptors specific for cd19
WO2010096434A3 (fr) Protéines de liaison spécifique et leurs utilisations
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
WO2013181543A8 (fr) Anticorps monoclonaux à affinité élevée contre le glypicane 3 et utilisation de ceux-ci
WO2016077840A3 (fr) Composés de liaison sélectifs de tfr et procédés associés
WO2011106300A3 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
WO2009014708A3 (fr) Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
TN2012000159A1 (en) Monoclonal antibodies to progastrin and their uses
MX349096B (es) Anticuerpos anti-pd-l1 y sus usos.
WO2012047317A3 (fr) Anticorps spécifiques à une tumeur et utilisations de ceux-ci
WO2010145796A3 (fr) Biomarqueurs et procédés pour déterminer l'efficacité d'anticorps anti-egfr dans une thérapie d'un cancer
WO2011041319A3 (fr) Protéines de liaison spécifiques et leurs utilisations
WO2009032949A3 (fr) Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
WO2010059969A8 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2014008206A3 (fr) Potentiel diagnostique et thérapeutique d'anticorps igg monoclonaux monospécifiques du hla-e dirigés contre la surface des cellules tumorales et hla-e soluble
WO2014153056A3 (fr) Traitement anticancéreux à l'aide d'anticorps qui se lient à grp78 de surface cellulaire
CA2888908A1 (fr) Anticorps contre l'antigene 1 associe aux reins et leurs fragments de liaison a l'antigene
WO2016123591A3 (fr) Compositions et méthodes de traitement et de détection de cancers
WO2011145085A3 (fr) Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749515

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11749515

Country of ref document: EP

Kind code of ref document: A2